Close Menu

CareDx

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.

CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.

The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.

The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.

The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.

The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.

Pages

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.